Prolia (Denosumab): What People Actually Pay

The List Price vs. What Patients Report Paying

Prolia's wholesale acquisition cost (WAC) is approximately $1,786 per prefilled syringe, which translates to roughly $3,572 annually for the standard twice-yearly dosing schedule. That number rarely reflects what insured patients hand over at the point of care.

Across patient forums including Reddit's r/osteoporosis and Drugs.com review boards, commercial insurance holders consistently describe copays between $0 and $50 per injection when using Amgen's copay assistance program. One Drugs.com reviewer wrote: "My insurance covers it as a specialty drug and with the Amgen card I paid zero both times this year." Another poster on Reddit's r/osteoporosis reported: "Without the savings card my copay was going to be $800. With it, $5." These anecdotes align with Amgen's published offer of reducing eligible patients' out-of-pocket costs to as low as $0 per injection, with a maximum benefit per dose.

Selection bias matters here. Patients motivated to post online skew toward those with notably good or notably bad financial experiences. The middle range of copays ($100 to $300 for commercially insured patients without copay assistance) is likely underrepresented in forum discussions. A 2022 analysis published in the Journal of Managed Care & Specialty Pharmacy found that mean out-of-pocket costs for denosumab under commercial plans averaged $148 per claim, a figure that accounts for the full distribution of plan designs.

Medicare Coverage: The 20% Problem

Medicare Part B covers Prolia when administered in a physician's office, classifying it as a physician-administered injectable. The patient owes 20% coinsurance after meeting the Part B deductible ($257 in 2025). On a Medicare-allowable amount near $1,600 per injection, that coinsurance works out to roughly $320 per dose, or about $640 per year.

Supplemental Medigap policies (Plans C, F, or G) can reduce or eliminate that coinsurance. Patients with Medicare Advantage plans face variable cost-sharing depending on their specific plan's formulary tier and specialty drug rules. Forum reports from Medicare beneficiaries show wide variance. One Reddit user in r/Medicare wrote: "I have Plan G supplement and paid nothing out of pocket for my Prolia shot." A Drugs.com reviewer on original Medicare without a supplement reported paying "$347 at my rheumatologist's office."

Amgen's copay card is not available to patients whose drug costs are reimbursed by any federal healthcare program, including Medicare, Medicaid, and TRICARE. This restriction leaves Medicare patients without supplemental coverage facing the full 20% coinsurance. The Amgen Safety Net Foundation, a separate program, provides Prolia at no cost to qualifying patients based on income and insurance status, but the application process takes 4 to 8 weeks and requires annual renewal.

How Prolia Costs Compare to Oral Bisphosphonates

The cost gap between Prolia and generic oral bisphosphonates is substantial. Generic alendronate (the active ingredient in Fosamax) costs $4 to $20 per month at most retail pharmacies, translating to $48 to $240 per year. Generic risedronate runs slightly higher but remains under $400 annually in most markets. Prolia's annual list price is 9 to 74 times higher than these alternatives.

That price difference raises a question patients frequently ask their physicians: is the added cost justified? The answer depends on clinical context. The FREEDOM trial (N=7,868) demonstrated that denosumab 60 mg every 6 months reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over 36 months compared to placebo [1]. Head-to-head data against alendronate from the DECIDE trial showed denosumab produced greater gains in bone mineral density (BMD) at the total hip (3.5% vs. 2.6%) and lumbar spine (5.3% vs. 4.2%) over 12 months, though fracture endpoints were not powered in that study.

For patients who cannot tolerate oral bisphosphonates due to esophageal disorders, who have poor adherence to weekly or monthly pill regimens, or who have renal impairment (eGFR <30 to 35 mL/min, where bisphosphonates are contraindicated), Prolia fills a clinical gap that generic alternatives cannot. The twice-yearly injection schedule also produces higher real-world adherence rates. A retrospective cohort study of 1,278 postmenopausal women found 12-month persistence with denosumab was 82.4% compared to 57.8% for oral bisphosphonates.

The Hidden Costs: Administration Fees and Lab Work

Prolia's sticker price does not capture the full annual spend. Because denosumab requires subcutaneous injection by a healthcare provider every six months, patients incur office visit charges and administration fees on top of the drug cost.

A typical office visit for Prolia administration bills under CPT code 96372 (therapeutic subcutaneous injection). Medicare reimburses approximately $25 to $40 for this code, but commercial plan allowed amounts vary from $30 to $150 depending on geography and facility type. Patients receiving Prolia at hospital outpatient infusion centers often face facility fees that can add $200 to $500 per visit. Several Reddit users have flagged this discrepancy. One poster noted: "Same drug, same dose. My doctor's office billed $1,900 total. The hospital outpatient center quoted me $3,400."

Lab monitoring adds another layer. The Endocrine Society's clinical practice guidelines recommend checking serum calcium and 25-hydroxyvitamin D before initiating denosumab, with periodic monitoring during treatment. A basic metabolic panel runs $10 to $50 with insurance; vitamin D levels cost $20 to $80. Bone density scans (DXA) are typically performed every 2 years during treatment, adding $150 to $350 per scan depending on insurance and location. These ancillary costs can add $200 to $600 annually to the total cost of Prolia therapy.

Patient Assistance and Savings Programs

Amgen operates two distinct programs that affect out-of-pocket costs for Prolia. Understanding which one applies requires knowing the patient's insurance type.

The Amgen FIRST STEP copay card is available to commercially insured patients. It covers copay and coinsurance amounts up to a specified maximum per injection (historically $1,750 per dose). Patients present the card at their provider's office, and the program reimburses the copay directly. Enrollment requires no income verification. The card cannot be used with government insurance (Medicare, Medicaid, TRICARE, VA). As of 2025, Amgen reports that over 70% of commercially insured Prolia patients use some form of copay assistance.

The Amgen Safety Net Foundation serves uninsured patients and those on government insurance who meet income thresholds (generally at or below 300% of the federal poverty level, or roughly $46,000 for an individual in 2025). Approved patients receive Prolia at no cost, shipped directly to their physician's office. The program requires a new application each year with income documentation.

For Medicare patients above the Safety Net income threshold, options narrow considerably. Some Medicare Advantage plans place Prolia on lower cost-sharing tiers. Patients can also ask their provider to verify that Part B (physician-administered) billing applies rather than Part D (pharmacy benefit), since Part B coinsurance is often lower than Part D specialty tier copays. Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, has noted: "The financial toxicity of osteoporosis drugs is a real barrier to treatment. We lose patients not because the drugs don't work, but because they can't afford them."

What Forum Reviewers Report Paying: A Sample

Patient-reported costs from online forums and review sites paint a granular picture, though these reports carry inherent selection and recall bias. Sample sizes on any single platform are small (Drugs.com lists approximately 200 Prolia reviews; Reddit threads mentioning Prolia cost number fewer than 100 substantive posts). With those limitations stated, here is what patients describe.

On Drugs.com (filtering reviews that mention cost), the most common reported copay for commercially insured patients using the Amgen card is $0. Several reviewers describe initial sticker shock at the pre-card price followed by relief at the post-card price. A representative comment: "Pharmacy quoted $1,800. With the Amgen card, $0. I almost didn't get the shot because of the first number."

On Reddit (r/osteoporosis, r/HealthInsurance, r/Medicare), Medicare patients report the widest variance. Posts range from $0 (with Medigap supplement covering the coinsurance) to $380 (original Medicare, no supplement). One poster on r/HealthInsurance described fighting a prior authorization denial for 6 weeks before getting coverage approved.

Trustpilot reviews of Prolia are sparse and skew toward negative experiences overall (a pattern consistent across most prescription drug Trustpilot pages, where users are more likely to post after adverse events than positive outcomes). Cost complaints on Trustpilot tend to focus on unexpected facility fees rather than drug cost itself.

On PatientsLikeMe, the sample is too small (fewer than 30 profiles listing denosumab) to draw meaningful cost conclusions, though reported satisfaction with insurance coverage trends positive among those who do report.

The Discontinuation Cost Trap

One financial consideration unique to Prolia deserves attention: the cost of stopping. Unlike bisphosphonates, which deposit in bone and provide residual protection for months to years after discontinuation, denosumab's effects reverse rapidly once injections stop. A post-hoc analysis of the FREEDOM extension trial showed that patients who discontinued denosumab after long-term use experienced accelerated bone turnover and a rebound increase in vertebral fracture risk, with multiple vertebral fractures occurring in some patients within 7 to 12 months of the last dose.

Clinical guidelines from the American Association of Clinical Endocrinology now recommend that patients who stop Prolia should transition to a bisphosphonate (typically zoledronic acid infusion or oral alendronate) to mitigate rebound bone loss. This transition itself carries costs: a zoledronic acid infusion runs $300 to $1,200 depending on insurance, and the oral bisphosphonate alternative requires 1 to 2 years of continued therapy.

The implication for cost planning is clear. Starting Prolia is not a single financial decision. It is a commitment to ongoing treatment or a planned transition regimen. Patients and prescribers should factor transition costs into the total cost of care before initiating therapy. A Drugs.com reviewer captured this reality: "Nobody told me that once you start Prolia, you basically can't just stop. I wish I'd known that before my first injection."

Insurance Prior Authorization Patterns

Most commercial insurers and Medicare Advantage plans require prior authorization for Prolia. Common approval criteria include a documented diagnosis of osteoporosis (T-score of -2.5 or below at the hip or spine, or prior fragility fracture), failure of or contraindication to at least one oral bisphosphonate, and documentation of adequate calcium and vitamin D intake.

Step therapy requirements are the most frequent source of patient frustration in forum discussions. Plans that mandate a 6 to 12 month trial of generic alendronate before approving Prolia create delays for patients whose physicians believe Prolia is the appropriate first-line choice. The appeals process for step therapy exceptions typically takes 2 to 4 weeks. In the FREEDOM trial, the median age of enrolled participants was 72 years [1], and real-world Prolia patients trend older, making insurance navigation particularly burdensome for this population.

Some plans have moved Prolia to medical benefit (billed through the provider's office under Part B-style coverage) rather than pharmacy benefit, which can shift the cost-sharing structure. Patients should ask their insurer whether Prolia is covered under their medical benefit or pharmacy benefit, as the copay or coinsurance percentage may differ substantially between the two.

Biosimilar Outlook and Future Pricing

No FDA-approved biosimilar of Prolia (denosumab) is available in the United States as of May 2026. Amgen's key patents on denosumab have faced challenges, and several manufacturers including Samsung Bioepis and Sandoz have biosimilar candidates in late-stage development. The FDA's biosimilar action plan tracks pending applications, though specific approval dates remain uncertain.

Based on biosimilar pricing patterns observed with other biologics (adalimumab biosimilars launched at 55% to 85% of the reference product's list price), a denosumab biosimilar could reduce per-injection costs to $950 to $1,500 at launch. The actual impact on patient out-of-pocket costs will depend on formulary placement decisions by pharmacy benefit managers and whether biosimilar manufacturers offer their own copay assistance programs.

For patients currently on Prolia, the practical advice is straightforward: continue current coverage and copay assistance arrangements, and discuss biosimilar options with your prescriber once they become available. Switching from a reference biologic to a biosimilar mid-treatment requires a new prescription and potentially a new prior authorization, but clinical data from other biosimilar transitions show no meaningful difference in efficacy or safety.